Chabiotech Co.,Ltd. Logo

Chabiotech Co.,Ltd.

Develops cell/gene therapies and offers CDMO, biobanking, and genomics services for rare diseases.

085660 | KO

Overview

Corporate Details

ISIN(s):
KR7085660009
LEI:
Country:
South Korea
Address:
서울특별시 강남구 도산대로 442 청담동 피엔폴루스 3층, 강남구
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

CHA Biotech is a global biotechnology company at the forefront of developing innovative cell and gene therapies for rare cancers and incurable diseases. The company leverages its significant expertise in stem cell technology, ranking among the top globally for patent applications in the field. Its core business operations are diversified across several key areas: a world-class Contract Development and Manufacturing Organization (CDMO) specializing in advanced biopharmaceuticals; comprehensive biobanking services, including cord blood (i-Cord) and immune cell storage (Bio Insurance); and precision medicine through its genomics division. Additionally, CHA Biotech develops digital healthcare platforms, offers wellness programs (CHAUM), and provides healthcare consulting. The company's unique strength lies in its vertically integrated model, which spans from R&D and manufacturing to clinical application through an extensive global network of hospitals and medical centers across seven countries.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-18 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (조기난소부전 환자에서의 CordSTEM-ST의 안전성 및 내약성을 평가하기 위한…
Korean 22.9 KB
2025-09-08 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 222.3 KB
2025-08-25 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 228.6 KB
2025-08-13 00:00
Annual Report
[기재정정]사업보고서 (2024.12)
Korean 4.7 MB
2025-08-13 00:00
Interim Report
반기보고서 (2025.06)
Korean 8.5 MB
2025-08-04 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.7 KB
2025-07-24 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.6 KB
2025-07-24 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 229.8 KB
2025-07-24 00:00
Legal Proceedings Report
투자판단관련주요경영사항(임상시험결과) (알츠하이머병 환자에서 CB-AC-02 치료의 안전성과 잠재적 치료효과를 평가하기…
Korean 15.3 KB
2025-07-17 00:00
Share Issue/Capital Change
전환주식의전환가액조정 (상환전환우선주)
Korean 13.8 KB
2025-07-16 00:00
Share Issue/Capital Change
전환가액의조정
Korean 14.1 KB
2025-07-16 00:00
Share Issue/Capital Change
신주인수권행사가액의조정
Korean 14.3 KB
2025-06-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-06-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB
2025-06-23 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 25.7 KB

Automate Your Workflow. Get a real-time feed of all Chabiotech Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Chabiotech Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Chabiotech Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Nuvectis Pharma, Inc. Logo
Clinical-stage biopharma developing precision medicines for serious oncological conditions.
United States of America
NVCT
Nykode Therapeutics ASA Logo
Developing novel immunotherapies and vaccines for cancer with its antigen-targeting platform.
Norway
NYKD
Ocugen, Inc. Logo
Develops gene/cell therapies and vaccines, specializing in blindness and public health.
United States of America
OCGN
Oculis Holding AG Logo
Clinical-stage biopharma developing non-invasive eye drops for sight-threatening diseases.
Switzerland
OCS
OKYO Pharma Ltd Logo
Biopharma developing novel drugs for inflammatory eye diseases and neuropathic corneal pain.
United States of America
OKYO
OLIPASS CORPORATION Logo
Biotech firm developing RNA therapeutics for diseases with its proprietary OPNA platform.
South Korea
244460
A technology platform for pharma/biotech to discover therapeutic antibodies via transgenic animals.
United States of America
OABIW
Oncocross Co.,Ltd. Logo
AI-powered biotech accelerating drug development for cancer and rare diseases.
South Korea
382150
Onconic Therapeutics Inc. Logo
Develops novel drugs for cancer and GI diseases, including a next-gen acid blocker.
South Korea
476060
OncoTherapy Science, Inc. Logo
Develops targeted cancer therapies and provides TCR repertoire analysis services.
Japan
4564

Talk to a Data Expert

Have a question? We'll get back to you promptly.